BMY Stock Chart & Stats
$1075.00
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$720.00 - $1,189.97
Previous CloseN/A
VolumeN/A
Average Volume (3M)461.00
Market Cap
$2.22T
Enterprise Value$160.13K
Total Cash (Recent Filing)$10.49B
Total Debt (Recent Filing)$44.46B
Price to Earnings (P/E)17.4
Beta-0.16
Next Earnings
Jul 30, 2026EPS Estimate
27.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.56
Shares Outstanding2,042,071,300
10 Day Avg. Volume1,346
30 Day Avg. Volume461
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)5.96
Price to Sales (P/S)2.28
P/FCF Ratio8.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,108.53Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering18
EPS Forecast (FY)110.28
Revenue Forecast (FY)$825.00B
Bulls Say, Bears Say
Bulls Say
Growth Portfolio MomentumBMS’s diversified growth portfolio—led by Eliquis, Breyanzi, Reblozyl, Camzyos and others—has shown broad-based, repeatable commercial adoption. That reduces single-product dependence and provides multiple revenue drivers that can sustain mid-term top-line growth and offset legacy declines.
Strong Cash GenerationRobust operating and free cash flow, together with a sizable cash balance, gives BMS durable financial flexibility to fund R&D, pay dividends, pursue bolt-on M&A, and execute productivity programs without relying on capital markets—supporting strategic initiatives over the next 2–6 months.
R&D/AI & Pipeline InvestmentA material upgrade to DGX SuperPOD compute paired with stated R&D productivity targets (faster lead ID, shorter cycle times) creates structural capability to speed discovery and de‑risk development timelines, strengthening long‑term pipeline productivity and competitive positioning.
Bears Say
High LeverageElevated leverage materially reduces financial flexibility despite recent improvement from higher levels. It constrains capital allocation choices, raises refinancing risk if rates move, and limits ability to pursue large acquisitions or aggressive buybacks without deleveraging first.
Concentrated Late‑stage ReadoutsA cluster of high‑impact late‑2026 clinical and regulatory readouts concentrates binary execution risk. Failures or delays among a few pivotal programs could meaningfully alter the company’s growth trajectory and revenue outlook beyond the near term.
Margin Pressure & Legacy ErosionProduct mix shifts, a list‑price reduction for Eliquis and ongoing generic erosion in legacy medicines are compressing margins and net cash collections. These structural trends can weaken margin sustainability and cash conversion unless offset by higher‑margin growth brands or productivity gains.
BMY FAQ
What was Bristol-Myers Squibb Company’s price range in the past 12 months?
Bristol-Myers Squibb Company lowest stock price was $720.00 and its highest was $1189.97 in the past 12 months.
What is Bristol-Myers Squibb Company’s market cap?
Bristol-Myers Squibb Company’s market cap is $2.22T.
When is Bristol-Myers Squibb Company’s upcoming earnings report date?
Bristol-Myers Squibb Company’s upcoming earnings report date is Jul 30, 2026 which is in 4 days.
How were Bristol-Myers Squibb Company’s earnings last quarter?
Bristol-Myers Squibb Company released its earnings results on Apr 30, 2026. The company reported $27.664 earnings per share for the quarter, beating the consensus estimate of $24.933 by $2.731.
Is Bristol-Myers Squibb Company overvalued?
According to Wall Street analysts Bristol-Myers Squibb Company’s price is currently Undervalued.
Does Bristol-Myers Squibb Company pay dividends?
Bristol-Myers Squibb Company does not currently pay dividends.
What is Bristol-Myers Squibb Company’s EPS estimate?
Bristol-Myers Squibb Company’s EPS estimate is 27.94.
How many shares outstanding does Bristol-Myers Squibb Company have?
Bristol-Myers Squibb Company has 2,042,071,300 shares outstanding.
What happened to Bristol-Myers Squibb Company’s price movement after its last earnings report?
Bristol-Myers Squibb Company reported an EPS of $27.664 in its last earnings report, beating expectations of $24.933. Following the earnings report the stock price went up 2.989%.
Which hedge fund is a major shareholder of Bristol-Myers Squibb Company?
Currently, no hedge funds are holding shares in MX:BMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Bristol-Myers Squibb Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1,108.53 (― Downside)
$1,108.53 (― Downside)
Blogger Sentiment
Bullish
MX:BMY Sentiment 70%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
31.61%
12-Months-Change
Fundamentals
Return on Equity
3.91%
Trailing 12-Months
Asset Growth
-6.44%
Trailing 12-Months
Company Description
Bristol-Myers Squibb Company
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.
BMY Revenue Breakdown
54.80% Growth Portfolio
45.20% Legacy Portfolio
BMY Stock 12 Month Forecast
Average Price Target
$1,108.53